Harrow, Inc. (NASDAQ:HROW) Stock Has Average Target Price of $66.20

Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) have been assigned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $66.20.

HROW has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday, November 11th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Weiss Ratings upgraded shares of Harrow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, November 13th. Leerink Partners assumed coverage on shares of Harrow in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Read Our Latest Report on HROW

Harrow Stock Down 5.4%

HROW opened at $30.41 on Thursday. The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.12. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -38.99 and a beta of 0.18. The business has a 50-day moving average of $30.14 and a two-hundred day moving average of $37.20. Harrow has a 12 month low of $25.76 and a 12 month high of $54.85.

Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. The company had revenue of $99.30 million during the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. On average, research analysts expect that Harrow will post -0.50 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HROW. KBC Group NV purchased a new stake in Harrow during the first quarter valued at about $31,000. Sterling Capital Management LLC increased its stake in Harrow by 836.8% during the third quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock worth $33,000 after acquiring an additional 954 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Harrow during the third quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Harrow in the 3rd quarter worth about $59,000. Finally, First Bancorp Inc ME purchased a new position in shares of Harrow in the 2nd quarter worth about $64,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Featured Stories

Analyst Recommendations for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.